Tyra Biosciences, Inc. has announced the commencement of dosing for the first patient in its Phase 2 SURF302 clinical trial, evaluating the efficacy and safety of TYRA-300 in patients with low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC). TYRA-300 is currently the only orally administered investigational agent in clinical development for this condition. The trial aims to enroll up to 90 participants across multiple sites in the United States. Participants will receive either 50 mg or 60 mg of TYRA-300 once daily. The study's primary endpoint is the complete response rate at three months, with initial data expected in the first half of 2026. Secondary endpoints include recurrence metrics and safety evaluations. Results from the trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.